Inno-206
Kidney Tumor
Merck Sharp & Dohme LLCPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Kidney Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib Pfizer | Phase 3 | BB |
Ipilimumab Pfizer | Phase 4 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Sorafenib Pfizer | Phase 3 | B |
Alpha-Interferon Pfizer | Phase 3 | B |
View all 50 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →